Company Filing History:
Years Active: 2019
Title: Innovations of Thomas Nachreiner
Introduction
Thomas Nachreiner is an accomplished inventor based in Inden, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of human cytolytic fusion proteins. His work focuses on creating novel solutions that can induce apoptosis in human cells, which has important implications for medical research and treatment.
Latest Patents
Thomas Nachreiner holds 1 patent for his invention titled "Human cytolytic fusion proteins." This technology involves the creation of human cytolytic fusion proteins (hCFPs) that are designed to induce apoptosis in target human cells. The innovative aspect of his patent includes a target cell-specific binding component, which consists of an antibody or an antibody fragment that binds to the cellular surface receptor CD64. Additionally, the effector domain of these proteins comprises a variant of wild type human angiogenin or a functional fragment thereof. The patent also covers nucleic acid molecules encoding these recombinant hCFPs, as well as the vectors and host cells that contain these nucleic acids.
Career Highlights
Thomas Nachreiner is affiliated with the University of Cape Town, where he continues to advance his research in biotechnology. His work has garnered attention for its potential applications in therapeutic interventions and cancer treatment.
Collaborations
Throughout his career, Thomas has collaborated with notable colleagues, including Stefan Barth and Christian Cremer. These partnerships have contributed to the development and refinement of his innovative technologies.
Conclusion
Thomas Nachreiner's contributions to the field of biotechnology, particularly through his patent on human cytolytic fusion proteins, highlight his role as a significant inventor. His work not only advances scientific knowledge but also holds promise for future medical applications.